Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (12)

« Back to Publications

Facilitators and barriers affecting the implementation of e-health for chronic respiratory diseases in remote settings: a qualitative evidence synthesis.

Salmi EM. et al, (2025), BMC Health Serv Res, 25

FujiLAM for the diagnosis of childhood tuberculosis: a systematic review.

Olbrich L. et al, (2022), BMJ Paediatr Open, 6

Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nature medicine

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Functional Asplenia and Specific Polysaccharide Antibody Deficiency in a Girl with SAVI.

Bijker EM. et al, (2021), J Clin Immunol, 41, 495 - 497

guide to vaccinology: from basic principles to new developments.

Pollard AJ. and Bijker EM., (2021), Nat Rev Immunol, 21, 83 - 100

Publisher Correction: A guide to vaccinology: from basic principles to new developments

Pollard AJ. and Bijker EM., (2021), Nature Reviews Immunology

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial.

LAMBE T. et al, (2020), Nature Medicine

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

HODGSON S., (2020), The Lancet

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2020), Lancet

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2020), Nat Med